Emergent BioSolutions Inc. (EBS)Healthcare | Drug Manufacturers - Specialty & Generic | Gaithersburg, United States | NYSE
8.81 USD
+0.19
(2.204%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.84 +0.03 (0.341%) ⇧ (April 17, 2026, 7:53 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:15 a.m. EDT
Emergent BioSolutions is a critical long-term hold (0 stars) due to its eroding fundamentals, -23.6% revenue decline, and high debt maturities; despite the theoretical payout yield, it has no dividend history and fits the definition of a value trap (0 stars). Short-term movement is indecisive (2 stars) as the near-term 45-day forecast predicts a slight decline (-0.84%), and options data reveals queuers are actively hedging downside risk with long-dated puts rather than betting on a rally. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.271792 |
| MSTL | 0.274495 |
| AutoARIMA | 0.275024 |
| AutoTheta | 0.337822 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 16.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.043 |
| Excess Kurtosis | -1.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 111.692 |
| Revenue per Share | 13.886 |
| Market Cap | 456,101,248 |
| Trailing P/E | 9.47 |
| Forward P/E | 2.95 |
| Beta | 2.36 |
| Profit Margins | 7.08% |
| Website | https://www.emergentbiosolutions.com |
As of April 19, 2026, 12:15 a.m. EDT: Options flow indicates a defensive posture for speculators, not a directional bet on upside. For the 09/18 expiry, puts show heavy open interest (OI) concentration at the 8.0 and 9.0 strikes compared to trivial call volume, implying a strong 'gamma wall' or downside hedge at current price levels. Conversely, for the 2027-01-15 expiry, long-term puts show massive OI at the 3.0 and 7.0 strikes while calls are sparse, confirming long-dated downside insurance is the dominant sentiment. Trading activity in near-term calls is minimal relative to OI, suggesting traders are selling time value rather than building a strong near-term upside thesis.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.94052863 |
| Address1 | 300 Professional Drive |
| Address2 | Suite 400 |
| All Time High | 137.61 |
| All Time Low | 1.42 |
| Ask | 9.25 |
| Ask Size | 300 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 647,550 |
| Average Daily Volume3 Month | 881,461 |
| Average Volume | 881,461 |
| Average Volume10Days | 647,550 |
| Beta | 2.357 |
| Bid | 8.6 |
| Bid Size | 500 |
| Board Risk | 3 |
| Book Value | 10.025 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.81 |
| Current Ratio | 5.011 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.02 |
| Day Low | 8.7 |
| Debt To Equity | 111.692 |
| Display Name | Emergent BioSolutions |
| Earnings Call Timestamp End | 1,777,582,800 |
| Earnings Call Timestamp Start | 1,777,582,800 |
| Earnings Timestamp | 1,777,579,200 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | 208,900,000 |
| Ebitda Margins | 0.28120002 |
| Enterprise To Ebitda | 3.994 |
| Enterprise To Revenue | 1.123 |
| Enterprise Value | 834,401,280 |
| Eps Current Year | 0.52 |
| Eps Forward | 2.99 |
| Eps Trailing Twelve Months | 0.93 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 240 631 3203 |
| Fifty Day Average | 9.08 |
| Fifty Day Average Change | -0.2699995 |
| Fifty Day Average Change Percent | -0.029735629 |
| Fifty Two Week Change Percent | 94.052864 |
| Fifty Two Week High | 14.06 |
| Fifty Two Week High Change | -5.25 |
| Fifty Two Week High Change Percent | -0.3733997 |
| Fifty Two Week Low | 4.45 |
| Fifty Two Week Low Change | 4.3600006 |
| Fifty Two Week Low Change Percent | 0.9797755 |
| Fifty Two Week Range | 4.45 - 14.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,163,601,000,000 |
| Float Shares | 47,113,033 |
| Forward Eps | 2.99 |
| Forward P E | 2.9464884 |
| Free Cashflow | 205,387,504 |
| Full Exchange Name | NYSE |
| Full Time Employees | 900 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.49441 |
| Gross Profits | 367,300,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.018860001 |
| Held Percent Institutions | 0.8239 |
| Implied Shares Outstanding | 51,770,858 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome#node/150 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Emergent BioSolutions Inc. |
| Market | us_market |
| Market Cap | 456,101,248 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_13627017 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 52,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 454,988,000 |
| Number Of Analyst Opinions | 2 |
| Open | 8.9 |
| Operating Cashflow | 170,600,000 |
| Operating Margins | -0.15198 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.38 |
| Phone | 240 631 3200 |
| Post Market Change | 0.029999733 |
| Post Market Change Percent | 0.3405191 |
| Post Market Price | 8.84 |
| Post Market Time | 1,776,470,037 |
| Previous Close | 8.62 |
| Price Eps Current Year | 16.942308 |
| Price Hint | 2 |
| Price To Book | 0.8788031 |
| Price To Sales Trailing12 Months | 0.61394703 |
| Profit Margins | 0.0708 |
| Quick Ratio | 2.191 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.190001 |
| Regular Market Change Percent | 2.20418 |
| Regular Market Day High | 9.02 |
| Regular Market Day Low | 8.7 |
| Regular Market Day Range | 8.7 - 9.02 |
| Regular Market Open | 8.9 |
| Regular Market Previous Close | 8.62 |
| Regular Market Price | 8.81 |
| Regular Market Time | 1,776,456,003 |
| Regular Market Volume | 499,871 |
| Return On Assets | 0.05335 |
| Return On Equity | 0.10463 |
| Revenue Growth | -0.236 |
| Revenue Per Share | 13.886 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 51,644,495 |
| Shares Percent Shares Out | 0.1869 |
| Shares Short | 9,650,911 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,986,187 |
| Short Name | Emergent BioSolutions Inc. |
| Short Percent Of Float | 0.1898 |
| Short Ratio | 9.54 |
| Source Interval | 15 |
| State | MD |
| Symbol | EBS |
| Target High Price | 12.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 12.0 |
| Total Cash | 205,400,000 |
| Total Cash Per Share | 3.967 |
| Total Debt | 583,699,968 |
| Total Revenue | 742,899,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.93 |
| Trailing P E | 9.473119 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.5456 |
| Two Hundred Day Average Change | -0.7355995 |
| Two Hundred Day Average Change Percent | -0.07706163 |
| Type Disp | Equity |
| Volume | 499,871 |
| Website | https://www.emergentbiosolutions.com |
| Zip | 20,879 |